Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

被引:0
|
作者
Alexander M. M. Eggermont
Marna G. Bouwhuis
Wim H. Kruit
Alessandro Testori
Timo ten Hagen
Antoine Yver
Christine Xu
机构
[1] Erasmus University Medical Center,Department of Surgical Oncology
[2] Daniel den Hoed Cancer Center,Department of Medical Oncology
[3] Erasmus University Medical Center,Melanoma/Sarcoma Unit
[4] Daniel den Hoed Cancer Center,undefined
[5] European Institute of Oncology,undefined
[6] Schering-Plough Research Institute,undefined
来源
关键词
Peginterferon alfa-2b; Melanoma; Pharmacokinetics; Cytokines;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:671 / 677
页数:6
相关论文
共 50 条
  • [31] Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
    Eggermont, Alexander M. M.
    Suciu, Stefan
    Testori, Alessandro
    Kruit, Wim H.
    Marsden, Jeremy
    Punt, Cornelis J.
    Santinami, Mario
    Sales, Francois
    Schadendorf, Dirk
    Patel, Poulam
    Dummer, Reinhard
    Robert, Caroline
    Keilholz, Ulrich
    Yver, Antoine
    Spatz, Alan
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) : 218 - 225
  • [32] Does pegylated interferon α-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?
    Kirkwood, John M.
    Tawbi, Hussein A.
    Tarhini, Ahmad A.
    Moschos, Stergios J.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 70 - 71
  • [33] Does pegylated interferon α-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?
    John M Kirkwood
    Hussein A Tawbi
    Ahmad A Tarhini
    Stergios J Moschos
    [J]. Nature Clinical Practice Oncology, 2009, 6 : 70 - 71
  • [34] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    Kirkwood, John M.
    Tarhini, Ahmad A.
    Moschos, Stergios J.
    Panelli, Monica C.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 2 - 3
  • [35] Treatment of chronic hepatitis delta with pegylated interferon-α2b
    Erhardt, Andreas
    Gerlich, Wolfram
    Starke, Christine
    Wend, Ulrike
    Donner, Andreas
    Sagir, Abdurrahman
    Heintges, Tobias
    Haeussinger, Dieter
    [J]. LIVER INTERNATIONAL, 2006, 26 (07) : 805 - 810
  • [36] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    John M Kirkwood
    Ahmad A Tarhini
    Stergios J Moschos
    Monica C Panelli
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 2 - 3
  • [37] An update on pegylated IFN-α2b for the adjuvant treatment of melanoma
    Agarwala, Sanjiv S.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1449 - 1459
  • [38] A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence.
    Kim, K. B.
    Legha, S. S.
    Gonzalez, R.
    Anderson, C.
    Papadopoulos, N. E.
    Eton, O.
    Plager, C.
    Roe, A.
    Liu, P.
    Bedikian, A. Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 453S - 453S
  • [39] Pegylated interferon α-2b, ribavirin and amantadine for chronic hepatitis C
    Younossi, ZM
    McCullough, A
    Barnes, D
    Post, A
    Ong, J
    O'Shea, R
    Martin, LM
    Bringman, D
    Farmer, D
    Levinthal, G
    Mullen, KD
    Carey, WD
    Tavill, AS
    Ferguson, R
    Gramlich, T
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (05) : 970 - 975
  • [40] Pegylated Interferon α-2b, Ribavirin and Amantadine for Chronic Hepatitis C
    Zobair M. Younossi
    Arthur C. McCullough
    David S. Barnes
    Anthony Post
    Janus P. Ong
    Robert O’shea
    Lisa M. Martin
    Diane Bringman
    Denise Farmer
    Gavin Levinthal
    Kevin D. Mullen
    William D. Carey
    Anthony S. Tavill
    Roy Ferguson
    Terry Gramlich
    [J]. Digestive Diseases and Sciences, 2005, 50 : 970 - 975